Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

Strategy Insights - The report emphasizes the importance of controlling volatility and focusing on new energy sectors while recognizing the resilience of domestic demand [1] - The current geopolitical tensions, particularly in the Middle East, have led to significant uncertainty in global financial markets, impacting trading strategies [3][8] - The report categorizes assets into three types based on their correlation with the worsening Middle East situation: crisis trading, stagflation trading, and normalization trading [8][19] Group 1: Geopolitical Trading Logic - The report identifies three categories of overseas scenario trading assets: crisis trading, stagflation trading, and normalization trading, each with distinct characteristics and implications for investment strategies [8] - Crisis trading assets, such as energy and shipping, are directly affected by supply shocks and are expected to gain risk premiums [8] - Stagflation trading focuses on assets that can withstand supply shocks, such as gold and domestic demand assets, which are expected to show relative stability [8][19] Group 2: Focus on New Energy and Domestic Demand - The report highlights that new energy sectors, including wind, solar, and lithium batteries, are expected to benefit from the current geopolitical landscape and have a strong mid-term outlook [3][41] - Domestic demand-related sectors, such as food and beverage, beauty care, real estate, pharmaceuticals, retail, and banking, are noted for their low volatility, with historical volatility levels below 50% [3][41] - The report anticipates a stabilization and potential recovery in domestic prices, further supporting the outlook for these sectors [3][41] Group 3: Fertilizer and Semiconductor Materials - The report points out that the fertilizer sector, particularly nitrogen, phosphorus, and potassium fertilizers, is facing supply disruptions due to geopolitical tensions, with the Middle East being a critical supplier [23][24] - The report also highlights the potential impact on semiconductor materials, particularly helium, due to supply disruptions from Qatar, which could significantly affect the semiconductor industry [24][25] Group 4: Market Dynamics and Volatility - The report notes that the current market environment is dominated by crisis trading, with significant fluctuations in asset prices driven by geopolitical uncertainties [19][26] - It emphasizes the need to identify low-volatility assets that are less correlated with the ongoing geopolitical tensions, suggesting a focus on sectors with historically lower volatility [26][29] - The report indicates that the market is beginning to shift towards low-volatility sectors, reflecting a heightened demand for certainty amid rising overall market volatility [29]

Investment Rating - The report maintains an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [1]. Core Insights - The report emphasizes the unmet clinical needs in the cancer early screening field, highlighting the potential for investment opportunities in this area [1]. - The report notes that despite a recent decline in the pharmaceutical sector, the logic behind innovative drugs and devices remains unchanged, with domestic companies gradually enhancing their innovation capabilities [35]. Summary by Sections 1. Industry Performance - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of -0.13% against the CSI 300's 0.85% [22]. - For the week ending March 13, 2026, the CSI 300 rose by 0.19%, while the pharmaceutical sector fell by 0.22%, ranking 13th among 31 primary sub-industries [10][22]. 2. Market Dynamics - The report indicates that the pharmaceutical sector's valuation is currently at 33.5 times PE based on 2026 profit forecasts, which is a 27% premium over the overall A-share market (excluding financials) [23]. - The TTM valuation is 30.3 times PE, which is below the historical average of 34.9 times PE, indicating a 9.9% premium over the overall A-share market [23]. 3. Key Company Focus - The report highlights MIRXES (觅瑞), a leading company in cancer screening, which focuses on RNA technology and multi-cancer early screening. It is the only listed cancer screening company in Asia and has a strong patent portfolio [12][14]. - MIRXES is expected to deepen its market presence in Asia-Pacific and accelerate global expansion, with significant projects in gastric cancer screening planned for 2026 [14]. 4. Individual Stock Performance - The report identifies several stocks to watch, including Aidi Pharmaceutical, Fuhong Hanlin, and others, suggesting potential investment opportunities in these companies [34][36].

1. Report Industry Investment Rating No information provided regarding the report industry investment rating. 2. Core View of the Report The convertible bond market declined this week. It is recommended that investors track market supply, policy rhythm, and geopolitical conflict disturbances, and make comprehensive judgments based on convertible bond terms and underlying stock conditions to select bonds in a refined manner [3]. 3. Summary by Relevant Catalogs Market Conditions - From March 9 to March 13, 2026 (5 trading days), the CSI Convertible Bond Index had a change of -1.10% (last week's change was -2.07%), and the CSI All-Share Index changed by -0.51% (last week's change was -2.28%). Since 2026, the CSI Convertible Bond Index has changed by +3.41%, and the CSI All-Share Index has changed by +5.09% [1]. - By rating, high-rated bonds (AAA), medium-high-rated bonds (AA+), medium-rated bonds (AA), medium-low-rated bonds (AA-), and low-rated bonds (AA- and below) had weekly changes of +0.02%, -0.79%, -1.83%, -2.55%, and -1.97% respectively. High-rated bonds rose, while the rest declined [1]. - By convertible bond scale, large-scale convertible bonds (bond balance > 2 billion yuan), medium-large-scale convertible bonds (balance between 1.5 and 2 billion yuan), medium-scale convertible bonds (balance between 1 and 1.5 billion yuan), small-medium-scale convertible bonds (balance between 0.5 and 1 billion yuan), and small-scale convertible bonds (balance < 0.5 billion yuan) had weekly changes of -0.27%, +0.02%, +0.05%, -2.11%, and -2.75% respectively. Medium-large-scale and medium-scale convertible bonds rose, while the rest declined [2]. - By parity, ultra-high parity bonds (conversion value > 130 yuan), high parity bonds (conversion value between 120 and 130 yuan), medium-high parity bonds (conversion value between 110 and 120 yuan), medium parity bonds (conversion value between 100 and 110 yuan), medium-low parity bonds (conversion value between 90 and 100 yuan), low parity bonds (conversion value between 80 and 90 yuan), and ultra-low parity bonds (conversion value < 80 yuan) had weekly changes of -6.78%, -3.29%, -0.36%, -1.46%, -1.71%, -0.88%, and +0.07% respectively. All except ultra-low parity bonds declined [2]. Current Convertible Bond Valuation Levels As of March 13, 2026, there were 377 outstanding convertible bonds (382 at the end of last week), with a balance of 527.921 billion yuan (532.506 billion yuan at the end of last week). Specifically: - The average convertible bond price was 139.04 yuan (139.31 yuan at the end of last week), with a percentile of 96.49% (from the beginning of 2023 to March 13, 2026, the same below). - The average convertible bond parity was 108.59 yuan (106.74 yuan at the end of last week), with a percentile of 97.79%. - The average convertible bond conversion premium rate was 29.05% (31.15% at the end of last week), with a percentile of 22.76% [3]. Convertible Bond Increase Situation The top 15 convertible bonds in terms of increase this week are as follows: | Serial Number | Convertible Bond Abbreviation | Underlying Stock Abbreviation | Industry | Latest Closing Price (yuan) | Convertible Bond Increase (%) | Underlying Stock Increase (%) | | --- | --- | --- | --- | --- | --- | --- | | 1 | Wankai Convertible Bond | Wankai New Materials | Basic Chemicals | 262.02 | 19.61 | 22.58 | | 2 | Baichuan Convertible Bond 2 | Baichuan Co., Ltd. | Basic Chemicals | 200.58 | 16.16 | 18.06 | | 3 | Hebang Convertible Bond | Hebang Biotechnology | Basic Chemicals | 185.67 | 16.15 | 13.10 | | 4 | Xinfu Convertible Bond | SANGFOR Technologies | Computer | 116.60 | 10.24 | 2.21 | | 5 | Lianrui Convertible Bond | Lianrui New Materials | Basic Chemicals | 228.18 | 10.20 | 21.33 | | 6 | Dazhong Convertible Bond | Dazhong Mining | Steel | 412.99 | 8.68 | 10.30 | | 7 | Tongyu Convertible Bond | Tongyu Heavy Industry | Power Equipment | 153.00 | 7.59 | 28.35 | | 8 | Rong 23 Convertible Bond | Rongsheng Environmental Protection | Light Industry Manufacturing | 143.52 | 7.05 | 7.65 | | 9 | Jinlang Convertible Bond 02 | Jinlang Technology | Power Equipment | 182.17 | 6.53 | 16.03 | | 10 | Zhoubang Convertible Bond | Shenzhen Capchem Technology | Power Equipment | 184.40 | 5.93 | 8.61 | | 11 | Huati Convertible Bond | Huati Technology | Electronics | 124.09 | 5.32 | 9.43 | | 12 | Hengyi Convertible Bond 2 | Hengyi Petrochemical | Petroleum and Petrochemicals | 150.47 | 5.30 | -1.16 | | 13 | Yiwei Convertible Bond | EVE Energy | Power Equipment | 168.80 | 4.99 | 13.13 | | 14 | Shangtai Convertible Bond | Shangtai Technology | Power Equipment | 155.00 | 4.74 | 14.25 | | 15 | Lanfan Convertible Bond | Bluestar Medical | Medical Biology | 113.75 | 4.21 | 14.83 | [19]

Core Viewpoint - The article discusses the strong performance of the CSI 1000 Index and its enhanced strategy, highlighting its superior returns in various time frames and the underlying factors contributing to its success [2][4][10]. Group 1: Performance Overview - Since the beginning of 2026, the CSI 1000 Index has increased by 8.61%, ranking just behind the CSI 500 and CSI 2000 indices [2]. - The private equity CSI 1000 enhanced strategy has achieved a return of 10.61% year-to-date in 2026, and over the past three and five years, it has outperformed all broad-based strategies with returns of 84.31% and 128.75%, respectively [4][15]. - The CSI 1000 enhanced strategy has shown high volatility and drawdown, yet maintains a leading Sharpe ratio compared to other broad-based strategies [17]. Group 2: Characteristics of CSI 1000 Enhanced Strategy - The CSI 1000 Index consists of 1,000 stocks ranked 801-1800 by market capitalization, focusing on small-cap companies, with an average market cap of approximately 16.2 billion [12]. - The index's top five sectors include electronics (14.45%), power equipment (9.72%), pharmaceuticals (8.59%), computers (8.12%), and machinery (7.52%), reflecting a "technology growth" characteristic [12]. - The strategy benefits from a high beta due to its focus on small-cap stocks, which exhibit greater price elasticity and market sentiment fluctuations [14]. Group 3: Market Inefficiencies and Alpha Generation - The article highlights that the inefficiencies in the market contribute to the generation of alpha, as stocks with lower analyst coverage tend to have pricing inefficiencies [22]. - The low analyst coverage of CSI 1000 constituents allows skilled managers to exploit these inefficiencies, leading to enhanced returns [22][23]. Group 4: Future Outlook and Policy Support - The expected net profit growth rate for the CSI 1000 Index in 2026 is projected at 25%, significantly higher than the overall market average of 18.9% and the CSI 300's 10.1% [25]. - Recent government policies aimed at supporting venture capital and technology innovation are expected to boost market sentiment towards small-cap growth stocks [25]. - The article suggests that the potential for excess returns in the CSI 1000 remains strong, supported by structural characteristics rather than cyclical phenomena [25]. Group 5: Investment Strategy for Individuals - Given the high volatility of the CSI 1000 enhanced strategy, a long-term holding approach is recommended to smooth out fluctuations and capture both beta and alpha returns [27]. - The strategy is suggested as a complementary aggressive satellite allocation alongside large-cap blue-chip stocks, rather than a concentrated bet [27].

Market Overview - The market shows a trend of simultaneous reduction in positions by both institutional and retail investors in the Sci-Tech Innovation Index, with a noticeable convergence in the outflow speed of institutional funds from the ChiNext Index and the entire A-share market since March 4 [6][7] - Institutional funds exhibited strong outflow momentum before March 4, which weakened afterward, indicating a volatile outflow pattern [6][7] - Retail investors displayed a gradual outflow from the Sci-Tech Innovation Index, maintaining a wait-and-see attitude [6][7] Fund Flow by Market Capitalization and Valuation Style - Institutional funds accelerated their outflow from high-valuation indices, while retail funds continued to flow into these indices, indicating a lack of style preference switch [16][17] - The divergence in net inflow rates between retail and institutional investors remains positive across various style indices, suggesting a more cautious approach from institutional investors [16][17] Fund Flow by Major Industry Style - Institutional funds are slowly returning to the cyclical manufacturing sector, with a shift from outflow to slow inflow observed after March 4 [22][23] - The market displays significant volatility in fund inflow acceleration for both technology and cyclical manufacturing sectors, reflecting strong market competition [22][23] Fund Flow by Primary Industry Upstream Resources - Institutional funds are experiencing significant outflows from non-ferrous metals, while the outflow from basic chemicals is stabilizing [28][29] - Retail funds are heavily flowing into non-ferrous metals, indicating a strong speculative interest [28][29] Midstream Materials & Manufacturing - The electric power equipment sector has seen cumulative net inflows from institutional funds, while defense and machinery sectors are experiencing fluctuating outflows [30][31] - Retail buying power has shown a phase of increase, with net inflow rates indicating stronger retail interest compared to institutional [30][31] Downstream Essential Consumption - Institutional funds have shown a slight net inflow into agriculture, forestry, animal husbandry, and fishery, while other sectors lack significant buying momentum [34][35] Downstream Discretionary Consumption - There is no significant inflow momentum from institutional funds in this sector, with notable outflows particularly in household appliances [37] TMT Sector - The TMT sector is characterized by strong small-order buying power, while institutional funds are showing fluctuating outflows in communication and electronics [40][41] Large Financials - Retail investors are favoring banks for defensive positioning, with significant net inflows, while institutional funds continue to show outflows in non-bank financials [48][49] Support Services - The public utilities sector is a trading hotspot, with institutional funds showing alternating net inflows and outflows, indicating significant volatility [54][55] Leverage Fund Situation - The growth rate of margin financing and securities lending balances has slowed, with the market average guarantee ratio showing adjustments, indicating manageable leverage risks [60][61] - As of March 12, the total margin financing and securities lending balance is approximately 2.66 trillion yuan, maintaining ample liquidity [60][61] - The overall trading activity in margin financing has declined, with the proportion of margin trading transactions decreasing to 9.67% [61][62]

Market Overview - The A-share market experienced an overall increase on March 10, with the Shanghai Composite Index closing at 4123.14 points, up 0.65%, the Shenzhen Component Index at 14354.07 points, up 2.04%, and the ChiNext Index at 3306.14 points, up 3.04% [1]. Capital Flow - The net inflow of main funds in the A-share market was 0.89 billion yuan, with an opening net inflow of 33.74 billion yuan and a closing net inflow of 3.78 billion yuan [2]. - The net inflow for the CSI 300 was 51.68 billion yuan, while the ChiNext saw a net inflow of 27.75 billion yuan, and the Sci-Tech Innovation Board experienced a net outflow of 13.37 billion yuan [4]. Sector Performance - The electronic industry led the net inflow among sectors with 265.34 billion yuan, followed by the communication sector with 145.36 billion yuan, and machinery equipment with 85.30 billion yuan [6][7]. - The computer sector had the highest net outflow at -70.41 billion yuan, followed by basic chemicals at -36.24 billion yuan, and coal at -32.01 billion yuan [7]. Institutional Activity - Institutions showed significant interest in several stocks, with notable net purchases in Guangxun Technology (24.57 million yuan) and Nanfang Digital (15.79 million yuan) [9][10]. - Conversely, institutions sold off stocks like Jinkai New Energy, which had a net sell of -45.98 million yuan [10]. Institutional Focus - Recent institutional ratings highlighted stocks such as Zhejiang Huayuan with a target price of 35.84 yuan, representing a potential upside of 19.39%, and Ningde Times with a target price of 618.00 yuan, indicating a 64.23% upside [11].

Investment Rating - The report assigns an "Accumulate" rating to Fosun International, with a target price of HKD 7.24 per share, based on a NAV valuation of HKD 18.1 per share [8]. Core Insights - The valuation is currently low, with a clear strategic focus on core sectors, continuous improvement in asset quality, and a steady increase in credit ratings. The company's operational fundamentals are improving, with expected earnings growth and upward performance potential [2]. Financial Summary - Total revenue projections (in million RMB) for 2024A to 2028E are as follows: - 2024A: 192,142 (-3.06%) - 2025E: 170,932 (-11.04%) - 2026E: 180,434 (+5.56%) - 2027E: 191,091 (+5.91%) - 2028E: 203,521 (+6.50%) [4] - Net profit projections show a significant turnaround from a loss of 4.35 billion in 2024A to a profit of 4.13 billion in 2028E, indicating a recovery trajectory [4]. Company Overview - Fosun International is positioned as a global family consumption industry group, focusing on health, happiness, wealth, and intelligent manufacturing sectors. The company aims to enhance family life through a comprehensive service offering [12][21]. - The company has undergone a strategic "slimming down" process, divesting non-core assets and focusing on its main business areas, which has led to improved asset quality and financial leverage [8][26]. Strategic Focus - The company is concentrating on four main sectors: health, happiness, wealth, and intelligent manufacturing. Each sector is designed to provide comprehensive services and products to global families [21][22]. - The health sector is focused on pharmaceuticals, diagnostics, and health services, while the happiness sector emphasizes leisure, cultural consumption, and fashion brands. The wealth sector is centered on insurance and asset management, and the intelligent manufacturing sector targets strategic resources and new materials [21][22]. Performance Outlook - The company is expected to experience a rebound in profitability, with improved operational quality driving valuation increases. The credit rating has been upgraded, and cost reductions are anticipated to enhance profit margins [4][8]. - The health sector's revenue is projected to remain stable, with significant contributions from innovative drug developments and medical services, while the happiness sector faces challenges due to market conditions [35][41].

Group 1 - In the first week of March, the total net inflow of funds into the market was 49.3 billion, an increase from the previous week's inflow of 44.2 billion [1] - The short-term sentiment indicator is at a medium-high level since 2005, while the long-term sentiment indicator is at a medium-low level since 2005 [1][2] - From an industry perspective, the sectors with the highest trading volume share in the past week were defense and military, communication, and electric power equipment, with shares of 99%, 98%, and 97% respectively [2][14] Group 2 - In terms of fund inflows, the financing balance decreased by 24.2 billion, public fund issuance increased by 2.7 billion, ETF net subscriptions were 1.6 billion, and northbound funds estimated a net outflow of 9.2 billion [8] - The long-term sentiment indicator shows that the A-share risk premium was 2.49%, placing it at the 46th percentile historically, while the dividend yield of the CSI 300 index (excluding finance) was 1.22, at the 6th percentile historically [2][14] - The sectors with the highest financing transaction share were machinery and equipment at 89%, social services at 79%, and electric power equipment at 75%, while the lowest were banking at 7%, comprehensive at 8%, and coal at 14% [2][14]

Market Overview - As of February 28, 2026, the number of listed companies on the Beijing Stock Exchange (BSE) reached 295, with a total market capitalization of 942.59 billion, and an average market value of 3.195 billion per company. The proportion of national-level specialized and innovative enterprises is approximately 61.02%, while high-tech enterprises account for 91.19% [6][8]. Index Performance - The BSE 50 Index and the Specialized and Innovative Index closed at 1537.13 and 2581.02 points respectively by the end of February 2026. The BSE 50 Index experienced a monthly fluctuation of 0.36%, while the Specialized and Innovative Index had a fluctuation of 0.39% [2][12]. - The PE (TTM, excluding negative values) for the BSE 50 Index was 48.65 times, while the Specialized and Innovative Index had the lowest PE (TTM, excluding negative values) among similar indices at 69.79 times [23][27]. Industry Performance - In February 2026, only the power equipment industry (2.97%) and the computer industry (2.08%) showed positive average fluctuations, while other industries had negative average fluctuations. Year-to-date, the power equipment and computer industries had impressive average fluctuations of 16.06% and 7.35% respectively, while the automotive industry had the lowest at -5.87% [39][44]. - The PE (TTM, excluding negative values) for the computer and electronics industries was notably high at 149.12 times and 73.42 times respectively, while other industries ranged from 32.79 times to 46.55 times [44]. Liquidity Situation - The trading volume for the BSE 50 Index fluctuated between 16.379 billion and 22.508 billion, while the Specialized and Innovative Index ranged from 4.983 billion to 6.477 billion. The turnover rates for the BSE 50 Index and the Specialized and Innovative Index were maintained at 1.59% to 2.84% and 2.40% to 2.97% respectively [31][33]. Company Announcements and Regulatory Dynamics - The BSE 50 sample stocks underwent periodic adjustments, with three stocks including Jikang Technology being added, while three stocks including Aweit were removed. Several key companies reported their 2025 performance forecasts, with Bianxing Technology showing a revenue and net profit growth of 69.56% and 80.91% year-on-year, respectively [60][62].